Stanozolol (Winstrol)
Stanozolol ('Winstrol', 'Winny') is a 17α-methylated DHT-derived steroid with a fused pyrazole ring, available orally and as an aqueous injectable. It does not aromatise and produces a dry, hardened look with strength gains rather than mass, making it a classic cutting and athletic-performance compound. It notably lowers HDL, strains the liver and is associated with joint discomfort.
01 Overview
Stanozolol became widely known after high-profile doping cases in track and field. Its pyrazole-modified structure blocks aromatisation entirely, so it adds no water and is used to improve definition, vascularity and strength-to-weight ratio rather than bulk.
Users value the 'dry' aesthetic and preserved leanness, but the same properties bring downsides: strongly adverse effects on cholesterol, dry and achy joints reported by many, and meaningful hepatotoxicity even in the injectable form (which is still 17α-alkylated). It has a comparatively long detection window, a repeated factor in sports anti-doping sanctions.
02 Mechanism
Androgen-receptor agonist derived from DHT with a [3,2-c]pyrazole ring; cannot aromatise, and lowers sex-hormone-binding globulin, raising free fraction of co-administered androgens.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Light | 10–20 mg/day | Oral | Entry range, often for women or definition work. |
| Common | 20–50 mg/day | Oral | Typical male cutting range. |
| Heavy | 50–100 mg/day | Oral | High dose; lipid and joint effects worsen markedly. |
Ester comparison
| Ester | Half-life | Injection freq. | Testosterone by mass |
|---|
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Improved muscle definition and hardnessAdds no water, producing a dry, hard, vascular appearance. | Observational | ||
| Increased strength without weight gainImproves strength-to-weight ratio, valued in weight-class sports. | Observational | ||
| Joint dryness and discomfortMany users report dry, achy joints during use. | Anecdotal |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Adverse lipid changesSharp reduction in HDL and rise in LDL, worsening cardiovascular risk. | Moderate | Very common | Clinical | |
| HepatotoxicityRaised transaminases; hepatotoxic even as the injectable form because it remains 17α-alkylated. | Moderate | Common | Clinical | |
| HPTA suppressionSuppresses endogenous testosterone. | Severe | Universal | Clinical |
06 Commonly used with
What stanozolol is combined with, and why. This is about intent rather than safety — the interactions table below covers what is dangerous. Nothing here is listed without what it costs.
| Compound | Frequency | Purpose & trade-off |
|---|---|---|
| Stacked compounds | ||
| Trenbolone acetatecontest prep | Combined in final contest-prep phases where both are non-aromatising and produce an exceptionally dry, hard, striated look.Trade-off: This is a harsh combination — Winstrol's joint-drying and lipid damage compound trenbolone's cardiovascular and neurological load. | |
| Support & ancillaries | ||
| TestosteroneTRT/base dose | Winstrol is strongly suppressive and non-aromatising, so a testosterone base is essential to keep androgen levels physiological and avoid low-testosterone symptoms.Trade-off: The testosterone base aromatises and adds water, which visually opposes the extreme dryness Winstrol is used to achieve. | |
| TUDCAliver support | Run with stanozolol to help protect the liver during use of this notably hepatotoxic C17-alkylated oral.Trade-off: It only partially offsets liver stress and does nothing for Winstrol's severe suppression of HDL and its drying, painful effect on joints. | |
| Post-cycle | ||
| ClomifenePCT | Used post-cycle to stimulate gonadotropins and recover endogenous testosterone after the suppression from stanozolol and the base.Trade-off: Recovery can be slow and incomplete, and clomifene often brings mood disturbance and visual side effects during PCT. | |